Skip to content
Back to meeting Original
Lorenza Rimassa· @LorenzaRimassa · X·· 14 hours agoScore70

HARMONI-GI1

Body

HARMONi-GI1: ivonescimab + chemo vs durvalumab + chemo in first-line advanced #BTC
-OS 14.9 vs 12.1 mos
-PFS 8.4 vs 5.8 mos
-ORR 53.8 vs 32.5%
A new standard of care in China. Do we need a trial in Western countries?
#ESMO26
#ESMOAmbassadors @myESMO

14 views · 0 likes · 0 reposts · 0 replies

引用@
The PD-1/VEGF bispecific antibody ivonescimab plus chemotherapy significantly improved overall survival in #BiliaryTractCancer in the phase III HARMONi-GI1 #ClinicalTrial presented in a Presidential Symposium at #ESMO26. Read more: 🔗 https://ow.ly/YtKV50ZZGRl #InsightsbyESMO
在 X 查看被引用的帖子

Source: Lorenza Rimassa · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.